(THRM) Gentherm - Overview
Stock: Seat Heaters, Climate Control, Battery Cooling, Patient Warming
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 41.1% |
| Relative Tail Risk | -13.8% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.29 |
| Alpha | -30.05 |
| Character TTM | |
|---|---|
| Beta | 0.978 |
| Beta Downside | 0.793 |
| Drawdowns 3y | |
|---|---|
| Max DD | 68.14% |
| CAGR/Max DD | -0.34 |
Description: THRM Gentherm January 20, 2026
Gentherm Inc. (NASDAQ: THRM) designs, develops, manufactures and sells thermal-management and pneumatic-comfort technologies for both automotive and medical markets. The firm operates two distinct segments: Automotive, which supplies seat-heaters, steering-wheel heaters, climate-control modules, pneumatic lumbar-massage systems and related electronic control units; and Medical, which offers temperature-management platforms (e.g., Blanketrol, Kool-Kit, Maxi-Therm) for hypothermia therapy, normothermia in surgery, and other patient-care applications.
Key recent performance metrics (FY 2023) show revenue of roughly **$1.2 billion**, a **45 % gross margin**, and adjusted earnings per share of **$1.10**, reflecting stable demand from light-vehicle OEMs and Tier-1 suppliers. The company generated **$180 million** of operating cash flow, enabling continued R&D investment in next-generation thermoelectric and battery-thermal solutions.
Two macro-level drivers underpin Gentherm’s outlook. First, the rapid electrification of vehicles raises the need for sophisticated battery-thermal-management systems, a market projected to grow at **CAGR ≈ 12 %** through 2030. Second, demographic aging and expanding intensive-care capacity in the U.S. and Europe boost demand for advanced patient temperature-management devices, a segment growing at **~8 %** annually.
Gentherm’s product portfolio is heavily integrated with original equipment manufacturers (OEMs) and Tier-1 suppliers, creating high switching costs and recurring revenue streams. However, the firm remains exposed to automotive cyclicality and the pace of EV adoption, which could accelerate or dampen near-term order volumes.
For a deeper, data-driven valuation framework, see the ValueRay profile on THRM.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 30.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 1.02 > 1.0 |
| NWC/Revenue: 26.32% < 20% (prev 25.27%; Δ 1.05% < -1%) |
| CFO/TA 0.09 > 3% & CFO 124.4m > Net Income 30.6m |
| Net Debt (-94.3m) to EBITDA (153.2m): -0.62 < 3 |
| Current Ratio: 1.96 > 1.5 & < 3 |
| Outstanding Shares: last quarter (30.7m) vs 12m ago -1.97% < -2% |
| Gross Margin: 24.13% > 18% (prev 0.26%; Δ 2388 % > 0.5%) |
| Asset Turnover: 109.3% > 50% (prev 113.2%; Δ -3.92% > 0%) |
| Interest Coverage Ratio: 7.24 > 6 (EBITDA TTM 153.2m / Interest Expense TTM 13.9m) |
Altman Z'' 5.14
| A: 0.28 (Total Current Assets 785.9m - Total Current Liabilities 400.3m) / Total Assets 1.38b |
| B: 0.51 (Retained Earnings 711.1m / Total Assets 1.38b) |
| C: 0.08 (EBIT TTM 101.0m / Avg Total Assets 1.34b) |
| D: 1.07 (Book Value of Equity 712.5m / Total Liabilities 663.4m) |
| Altman-Z'' Score: 5.14 = AAA |
Beneish M -3.01
| DSRI: 1.08 (Receivables 291.3m/270.9m, Revenue 1.46b/1.47b) |
| GMI: 1.06 (GM 24.13% / 25.62%) |
| AQI: 0.94 (AQ_t 0.20 / AQ_t-1 0.21) |
| SGI: 1.00 (Revenue 1.46b / 1.47b) |
| TATA: -0.07 (NI 30.6m - CFO 124.4m) / TA 1.38b) |
| Beneish M-Score: -3.01 (Cap -4..+1) = AA |
What is the price of THRM shares?
Over the past week, the price has changed by +0.75%, over one month by -16.39%, over three months by -10.47% and over the past year by -13.44%.
Is THRM a buy, sell or hold?
- StrongBuy: 2
- Buy: 1
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the THRM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 45.6 | 41.6% |
| Analysts Target Price | 45.6 | 41.6% |
| ValueRay Target Price | 25.6 | -20.5% |
THRM Fundamental Data Overview February 03, 2026
P/E Forward = 12.4224
P/S = 0.663
P/B = 1.3558
P/EG = 0.71
Revenue TTM = 1.46b USD
EBIT TTM = 101.0m USD
EBITDA TTM = 153.2m USD
Long Term Debt = 189.0m USD (from longTermDebt, last quarter)
Short Term Debt = 10.3m USD (from shortTermDebt, last quarter)
Debt = 60.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -94.3m USD (from netDebt column, last quarter)
Enterprise Value = 879.5m USD (973.8m + Debt 60.0m - CCE 154.2m)
Interest Coverage Ratio = 7.24 (Ebit TTM 101.0m / Interest Expense TTM 13.9m)
EV/FCF = 13.00x (Enterprise Value 879.5m / FCF TTM 67.7m)
FCF Yield = 7.69% (FCF TTM 67.7m / Enterprise Value 879.5m)
FCF Margin = 4.62% (FCF TTM 67.7m / Revenue TTM 1.46b)
Net Margin = 2.09% (Net Income TTM 30.6m / Revenue TTM 1.46b)
Gross Margin = 24.13% ((Revenue TTM 1.46b - Cost of Revenue TTM 1.11b) / Revenue TTM)
Gross Margin QoQ = 23.81% (prev 23.93%)
Tobins Q-Ratio = 0.64 (Enterprise Value 879.5m / Total Assets 1.38b)
Interest Expense / Debt = 5.52% (Interest Expense 3.31m / Debt 60.0m)
Taxrate = 28.42% (5.93m / 20.9m)
NOPAT = 72.3m (EBIT 101.0m * (1 - 28.42%))
Current Ratio = 1.96 (Total Current Assets 785.9m / Total Current Liabilities 400.3m)
Debt / Equity = 0.08 (Debt 60.0m / totalStockholderEquity, last quarter 717.9m)
Debt / EBITDA = -0.62 (Net Debt -94.3m / EBITDA 153.2m)
Debt / FCF = -1.39 (Net Debt -94.3m / FCF TTM 67.7m)
Total Stockholder Equity = 670.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 2.29% (Net Income 30.6m / Total Assets 1.38b)
RoE = 4.57% (Net Income TTM 30.6m / Total Stockholder Equity 670.3m)
RoCE = 11.75% (EBIT 101.0m / Capital Employed (Equity 670.3m + L.T.Debt 189.0m))
RoIC = 8.12% (NOPAT 72.3m / Invested Capital 890.4m)
WACC = 9.20% (E(973.8m)/V(1.03b) * Re(9.52%) + D(60.0m)/V(1.03b) * Rd(5.52%) * (1-Tc(0.28)))
Discount Rate = 9.52% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.28%
[DCF Debug] Terminal Value 74.43% ; FCFF base≈60.8m ; Y1≈63.0m ; Y5≈71.7m
Fair Price DCF = 36.34 (EV 1.01b - Net Debt -94.3m = Equity 1.11b / Shares 30.5m; r=9.20% [WACC]; 5y FCF grow 3.83% → 2.90% )
EPS Correlation: -8.24 | EPS CAGR: -43.17% | SUE: -2.79 | # QB: 0
Revenue Correlation: 76.11 | Revenue CAGR: 12.25% | SUE: 0.82 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.51 | Chg30d=-0.038 | Revisions Net=+2 | Analysts=3
EPS next Year (2026-12-31): EPS=2.57 | Chg30d=-0.065 | Revisions Net=-2 | Growth EPS=+8.7% | Growth Revenue=+2.2%